PRES1 CONTRIBUTES IN HEPATOCARCINOGENESIS IN PATIENTS WITH HBV INFECTION

PRES1 有助于 HBV 感染患者的肝癌发生

• 批准号: 11670510
• 负责人: ONISHI Saburo
• 金额: $ 2.3万
• 依托单位: KOCHI MEDICAL SCHOOL
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11670510/
• 关键词: HEPATITIS B VIRUS; HEPATOCELLULAR CARCINOMA; TRANSACTIVATION; CARCINOGENESIS; tronsactivation; preS1; TGF-α; transgenic mouse

Development of liver fibrosis results in hepatic failure, hepatocellular carcinoma, esophageal varices, and spontaneous peritonitis, which are life-threatening complications in liver cirrhosis. However, patients with chronic hepatitis B virus infection occasionally develop hepatocellular carcinoma in non-cirrhotic liver. Therefore, some unknown mechanisms are assumed to be involved in the process of hepatocarcinogenesis in chronic hepatitis B virus infection. HBX protein has been one of the candidates of such factors. Here we showed for the first time that HBV preS1 is another candidate protein involved in such a mechanism. It affects the feedforward mechanism of EGF-EGFR signalling pathway profoundly involved hepatocarcinogenesis. This novel evidence is important since it may contribute to elucidate the complex mechanism of hepatocarcinogenesis and to find a therapeutic path of hepatocarcinoma in the near future.

肝纤维化的发展导致肝衰竭、肝细胞癌、食管静脉曲张和自发性腹膜炎，这些是肝硬化中危及生命的并发症。然而，慢性B型肝炎病毒感染的患者偶尔会在非肝硬化的肝脏中发展为肝细胞癌。因此，推测慢性B型肝炎病毒感染的肝癌发生过程中可能存在一些未知的机制。HBX蛋白是这些因子的候选者之一。在这里，我们第一次表明，HBV前S1是另一个候选蛋白参与这种机制。它影响了EGF-EGFR信号通路的前馈机制，深刻地参与了肝癌的发生。这一新的证据是重要的，因为它可能有助于阐明复杂的肝癌发生机制，并在不久的将来找到肝癌的治疗途径。

项目成果

Kohsaki T, et al.: "Expression of UDP-GalNAc : polypeptide N-acetylgalacto-saminyltransferase isozymes T1 and T2 in human colorectal cancer."J Gastroenterol. 35. 840-8 (2000)

Kohsaki T 等人：“UDP-GalNAc 的表达：多肽 N-乙酰半乳糖氨基转移酶同工酶 T1 和 T2 在人结直肠癌中的表达。”J Gastroenterol。

Nemoto Y, et al.: "Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice."J Clin Invest. 105. 1819-1825 (2000)

Nemoto Y 等人：“芳香酶缺陷小鼠中脂肪酸代谢酶的表达发生改变。”J Clin Invest。

Murata Y, et al.: "Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients."Oncol Rep. 7. 1299-1304 (2000)

Murata Y 等人：“乳腺癌患者辅助他莫昔芬中未识别的肝脂肪变性和非酒精性脂肪性肝炎。”Oncol Rep. 7. 1299-1304 (2000)

Ono M,et al.: "Effects of Sho-saiko-to extract on liver fibrosis in relation to the change in hydroxyproline and retinoid levels of the liver in rats."J Pharm Pharmacol. 51. 1079-1084 (1999)

Ono M,et al.：“Sho-saiko-to 提取物对肝纤维化的影响与大鼠肝脏羟脯氨酸和类视黄醇水平的变化有关。”J Pharm Pharmacol。

T.Saibara, et al.: "Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis."Lancet. 353. 1802 (1999)

T.Saibara 等人：“苯扎贝特治疗他莫昔芬诱导的非酒精性脂肪性肝炎。”柳叶刀。